Beta receptor blocker therapy for the elderly in the COVID-19 era  

作　　者：Elpidio Santillo Monica Migale 

机构地区：[1]Geriatric Rehabilitative Department,IRCCS-INRCA,Fermo 63900,Italy

出　　处：《World Journal of Clinical Cases》2022年第23期8088-8096,共9页世界临床病例杂志

摘　　要：When the coronavirus disease 2019(COVID-19)pandemic spread globally from the Hubei region of China in December 2019,the impact on elderly people was particularly unfavorable.The mortality associated with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection was highest in older individuals,in whom frailty and comorbidities increased susceptibility to severe forms of COVID-19.Unfortunately,in older patients,the course of COVID-19 was often characterized by significant cardiovascular complications,such as heart failure decompensation,arrhythmias,pericarditis,and myopericarditis.Ensuring that the elderly have adequate therapeutic coverage against known cardiovascular diseases and risk factors is particularly important in the COVID-19 era.Beta blockers are widely used for the treatment and prevention of cardiovascular disease.The clinical benefits of beta blockers have been confirmed in elderly patients,and in addition to their negative chronotropic effect,sympathetic inhibition and anti-inflammatory activity are theoretically of great benefit for the treatment of COVID-19 infection.Beta blockers have not been clearly shown to prevent SARS-CoV-2 infection,but there is evidence from published studies including elderly patients that beta blockers are associated with a more favorable clinical course of COVID-19 and reduced mortality.In this minireview,we summarize the most important evidence available in the literature on the usefulness of beta blocker therapy for older patients in the context of the COVID-19 pandemic.

关 键 词：Adrenergic beta-antagonist COVID-19 Aged SARS-CoV-2 Cardiovascular diseases 

分 类 号：R563.1[医药卫生—呼吸系统]